Exhibit 99.1

LOGO

FOR RELEASE 4:00 PM EASTERN

WEDNESDAY, MARCH 4, 2015


CONTACTS:
Linda Lennox		Meara Murphy
Office: 978-671-8854		Office: 978-671-8508
Cell: 908-627-3424		Cell: 617-794-1045

Lantheus Medical Imaging Reports 2014 Fourth Quarter

and Full Year Financial Results

Fourth quarter worldwide revenue increases 7% as-reported and 9% constant currency; strong DEFINITY^® performance driven by continued market adoption and share gains

Fourth quarter Adjusted EBITDA increases 28% to $19.4 million; Company posts full year Adjusted EBITDA of $70.8 million

No. BILLERICA, Mass. (March 4, 2015) – Lantheus Medical Imaging, Inc. (“Lantheus” or “the Company”), a wholly-owned operating subsidiary of parent company Lantheus MI Intermediate, Inc. and a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, today reported financial results for its fourth quarter and full year ended December 31, 2014.

Worldwide revenue for the fourth quarter of 2014 totaled $77.0 million, representing a 7% increase as-reported and a 9% increase on a constant-currency basis over $71.7 million reported for the fourth quarter of 2013.

The Company reported quarterly GAAP-earnings profitability during the fourth quarter of 2014 with net income totaling $300,000, an improvement of $12.6 million over a net loss of $12.3 million reported for the fourth quarter of 2013.

Net income for the fourth quarter of 2014 included $1.2 million of non-cash costs associated with the Company’s previously-announced campus consolidation initiative. Net loss for the fourth quarter of 2013 included a $15.4 million non-cash charge for the write-down of certain intangibles, an $8.9 million credit for a special recovery from a manufacturer and a $0.4 million gain on a land sale.

The Company’s fourth quarter 2014 net income, as adjusted for the above items, totaled $1.5 million, an improvement of $7.6 million, compared to a net loss of $6.1 million for the fourth quarter of 2013. The attached financial tables include a reconciliation of U.S. GAAP to as-adjusted results.

The Company’s fourth quarter Adjusted EBITDA, as defined in the GAAP to non-GAAP reconciliation provided later in this release, was $19.4 million, increasing by 28% from $15.2 million in the same quarter of the prior year.

Jeff Bailey, President and CEO commented, “We are very pleased with our fourth quarter results and our strong finish to what has been an excellent year for Lantheus. Consistent with the themes we’ve experienced throughout 2014, our fourth quarter performance reflects continued, solid revenue growth and operating margin expansion, as well as sequential and year-over-year improvement in Adjusted EBITDA. Our strong quarterly sales performance for DEFINITY was driven by our continued success in expanding the appropriate use of contrast in cardiac echo procedures, while also growing our respective market share. With solid U.S. performances from all major product lines, our U.S. revenue growth accelerated to 12% during the fourth quarter, driving our adjusted operating and EBITDA margins to 17% and 25%, respectively.”

Mr. Bailey continued, “The improvement in our business fundamentals and operational efficiencies over the last two years is significant and provides a solid foundation as we enter 2015. Looking ahead, we are focused on a number of strategic and tactical objectives intended to further strengthen our business, our operating profile, and our ability to meet and exceed the needs of our customers. We look forward to pursuing these initiatives while creating additional opportunities to further improve our business and financial results.”

For the full year of 2014, worldwide revenue totaled $301.6 million, representing a 6% increase on an as-reported and an 8% increase on a constant-currency basis over $283.7 million reported for 2013. On a GAAP basis, the Company reported a net loss of $1.2 million for 2014, an improvement of $60.5 million over the net loss of $61.7 million for 2013. Full year GAAP results included the aforementioned fourth-quarter items and a $6.8 million write-down of land during the third quarter of 2013. Adjusted for those items, the Company achieved positive full year 2014 net income totaling $41,000, compared to a net loss of $48.7 million for 2013. The Company’s full year 2014 Adjusted EBITDA totaled $70.8 million, an improvement of $32.4 million over the $38.4 million reported for 2013. The attached financial tables include a reconciliation of U.S. GAAP to as-adjusted results.

Conference Call

As previously announced, the Company will host a conference call starting at 4:30 p.m. (Eastern Time) today. To access the live conference call via telephone, please dial 1-866-578-5771 (U.S. callers) or 1-617-213-8055 (international callers) and provide passcode 92067003. A live audio webcast of the call also will be available on the homepage of the Company’s website at www.lantheus.com. A replay of the telephone conference call and audio webcast will be available from approximately 8:30 p.m. ET on March 4, 2015 through midnight on April 1, 2015. To access a replay of the conference call, dial 1-888-286-8010 (U.S. callers) or 1-617-801-6888 (international callers), and provide passcode 55732560. A replay of this conference call will also be available in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as net sales excluding the impact of foreign currency, net income, as adjusted, EBITDA and Adjusted EBITDA. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. The measures may exclude such items which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company’s reported results of operations for a period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in the Company’s filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

About Lantheus Medical Imaging, Inc. and Lantheus MI Intermediate, Inc.

Lantheus Medical Imaging, Inc., a wholly-owned operating subsidiary of parent company, Lantheus MI Intermediate, Inc., is a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents. Lantheus provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. Key products include the echocardiography contrast agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon Xe 133 Gas (Xenon 133), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.

Lantheus has more than 500 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia.

– Tables Follow –

Lantheus MI Intermediate, Inc. and subsidiaries

Consolidated Statements of Operations

(dollars in thousands – unaudited)


	Three Months Ended December 31,						Year Ended December 31,
	2014			2013			2014			2013

Revenues	$	76,969		$	71,668		$	301,600		$	283,672
Cost of goods sold		44,208			61,787			176,081			206,311

Gross profit		32,761			9,881			125,519			77,361
Operating expenses:
Sales and marketing expenses		7,889			7,961			35,116			35,227
General and administrative expenses		8,357			7,481			34,921			33,159
Research and development expenses		4,715			5,031			13,673			30,459
Impairment of land		—			(382	)		—			6,406
Proceeds from manufacturer		—			(8,876	)		—			(8,876	)

Total operating expenses		20,961			11,215			83,710			96,375
Operating income (loss)		11,800			(1,334	)		41,809			(19,014	)
Interest expense, net		(10,557	)		(10,488	)		(42,261	)		(42,811	)
Other income (expense), net		626			267			478			1,161

Income (loss) before income taxes		1,869			(11,555	)		26			(60,664	)
Provision for income taxes		1,569			747			1,195			1,014

Net income (loss)	$	300		$	(12,302	)	$	(1,169	)	$	(61,678	)

Lantheus MI Intermediate, Inc. and subsidiaries

Consolidated Sales Analysis

(dollars in thousands – unaudited)


	Three Months Ended December 31,							Year Ended December 31,
	2014		2013		% change			2014		2013		% change
U.S.
DEFINITY		25,080		21,744		15.3	%		93,848		76,539		22.6	%
TechneLite		20,719		19,544		6.0	%		82,321		80,609		2.1	%
Xenon		9,023		7,970		13.2	%		36,542		32,086		13.9	%
Cardiolite		1,353		1,288		5.0	%		3,268		8,612		(62.1	)%
Other		5,537		4,603		20.3	%		20,541		15,793		30.1	%


Total U.S.	$	61,712	$	55,149		11.9	%	$	236,520	$	213,639		10.7	%


International
DEFINITY		545		418		30.4	%		1,912		1,555		23.0	%
TechneLite		2,691		2,548		5.6	%		11,267		11,586		(2.8	)%
Xenon		1		5		(80.0	)%		7		39		(82.1	)%
Cardiolite		3,305		4,110		(19.6	)%		15,555		17,525		(11.2	)%
Other		8,715		9,438		(7.7	)%		36,339		39,328		(7.6	)%

Total International	$	15,257	$	16,519		(7.6	)%	$	65,080	$	70,033		(7.1	)%


Worldwide
DEFINITY		25,625		22,162		15.6	%		95,760		78,094		22.6	%
TechneLite		23,410		22,092		6.0	%		93,588		92,195		1.5	%
Xenon		9,024		7,975		13.2	%		36,549		32,125		13.8	%
Cardiolite		4,658		5,398		(13.7	)%		18,823		26,137		(28.0	)%
Other		14,252		14,041		1.5	%		56,880		55,121		3.2	%


Total Revenues	$	76,969	$	71,668		7.4	%	$	301,600	$	283,672		6.3	%

Lantheus MI Intermediate, Inc. and subsidiaries

Supplemental Sales Information

(unaudited)


	December 31, 2014 Quarter-to-Date Sales Growth/(Decline)
	Domestic As Reported			Int’l Constant Currency			Int’l As Reported			Total Constant Currency			Total As Reported
Products
DEFINITY		15	%		41	%		30	%		16	%		16	%
TechneLite		6	%		13	%		6	%		7	%		6	%
Xenon		13	%		(71	)%		(80	)%		13	%		13	%
Cardiolite		5	%		(14	)%		(20	)%		(10	)%		(14	)%
Other		20	%		(2	)%		(8	)%		5	%		2	%

Total Revenues		12	%		(2	)%		(8	)%		9	%		7	%


	December 31, 2014 Year-to-Date Sales Growth/(Decline)
	Domestic As Reported			Int’l Constant Currency			Int’l As Reported			Total Constant Currency			Total As Reported
Products
DEFINITY		23	%		31	%		23	%		23	%		23	%
TechneLite		2	%		3	%		(3	)%		2	%		2	%
Xenon		14	%		(82	)%		(82	)%		14	%		14	%
Cardiolite		(62	)%		(7	)%		(11	)%		(25	)%		(28	)%
Other		30	%		(3	)%		(8	)%		7	%		3	%

Total Revenues		11	%		(2	)%		(7	)%		8	%		6	%

Lantheus MI Intermediate, Inc. and subsidiaries

Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency

(dollars in thousands – unaudited)


	Three Months Ended December 31, 2014				Year Ended December, 2014
	International Net Sales		Total Net Sales		International Net Sales		Total Net Sales

Net sales, as reported	$	15,257	$	76,969	$	65,080	$	301,600
Currency impact as compared to prior period		991		991		3,461		3,461

Net sales, excluding the impact of foreign currency	$	16,248	$	77,960	$	68,541	$	305,061

Lantheus MI Intermediate, Inc. and subsidiaries

Reconciliation of As Reported Results to Non-GAAP Financial Measures

(dollars in thousands – unaudited)


	Three Months Ended December 31,						Year Ended December 31,
	2014			2013			2014			2013
Net Income (loss)
Net income (loss), as reported	$	300		$	(12,302	)	$	(1,169	)	$	(61,678	)
Reconciling items impacting Gross Profit:
Intangible Impairment		—			15,440			—			15,440
Reconciling items impacting Operating Expenses:
Proceeds from Manufacturer		—			(8,876	)		—			(8,876	)
Campus Consolidation Costs		1,210			—			1,210			—
Impairment of Land		—			(382	)		—			6,406

Net income (loss), as adjusted	$	1,510		$	(6,120	)	$	41		$	(48,708	)


Net income (loss), as adjusted, as a percentage of net sales		2.0	%		(8.5	)%		0.0	%		(17.2	)%

Lantheus MI Intermediate, Inc. and subsidiaries

Reconciliation of As Reported Results to Non-GAAP Financial Measures

(dollars in thousands – unaudited)


	Three Months Ended December 31,						Year Ended December 31,
	2014			2013			2014			2013*
EBITDA
Net income (loss), as reported	$	300		$	(12,302	)	$	(1,169	)	$	(61,678	)
Interest expense, net		10,557			10,488			42,261			42,811
Provision (benefit) for income taxes		977			312			441			(127	)
Depreciation		3,387			2,221			9,901			9,336
Amortization of intangible assets		2,275			3,991			9,123			16,447

EBITDA		17,496			4,710			60,557			6,789
Reconciling items impacting EBITDA:
Non-cash stock-based compensation		249			(157	)		1,031			578
Legal fees relating to business interruption claim		186			108			1,113			660
Asset write-off		107			18,091			1,257			28,349
Severance and recruiting costs		306			270			818			5,239
Sponsor fee and other		248			260			1,020			1,457
New manufacturer costs		771			751			4,959			4,164
Proceeds from manufacturer		—			(8,876	)		—			(8,876	)

Adjusted EBITDA	$	19,363		$	15,157		$	70,775		$	38,360


Adjusted EBITDA as a percentage of net sales		25.2	%		21.1	%		23.5	%		13.5	%

Previously presented as excluding Proceeds from manufacturer as an Adjusted EBITDA reconciling item, resulting in 2013 Adjusted EBITDA of $47,236. Presentation of 2013 Adjusted EBITDA has been modified to allow better go-forward comparability by including Proceeds from manufacturer as an Adjusted EBITDA reconciling item, resulting in 2013 Adjusted EBITDA of $38,360.

Lantheus MI Intermediate, Inc. and subsidiaries

Reconciliation of Free Cash Flow

(dollars in thousands – unaudited)


	Three Months Ended						Year Ended
	December 31, 2014			December 31, 2013			December 31, 2014			December 31, 2013

Net cash provided by (used in) operating activities	$	(3,875	)	$	(3,856	)	$	11,573		$	(15,678	)
Capital expenditures		(2,834	)		(1,299	)		(8,137	)		(5,010	)

Free cash flow	$	(6,709	)	$	(5,155	)	$	3,436		$	(20,688	)

Lantheus MI Intermediate, Inc. and subsidiaries

Condensed Consolidated Balance Sheets

(dollars in thousands – unaudited)


	December 31, 2014			December 31, 2013
Assets
Current assets:
Cash and cash equivalents	$	17,817		$	16,669
Accounts receivable, net		41,540			38,910
Inventory		15,582			18,310
Income tax receivable		247			325
Deferred tax assets		256			18
Other current assets		3,739			3,087

Total current assets		79,181			77,319

Property, plant and equipment, net		96,014			97,653
Capitalized software development costs, net		2,421			1,470
Intangibles, net		27,191			34,998
Goodwill		15,714			15,714
Deferred financing costs		7,349			9,639
Deferred tax assets		328			15
Other long-term assets		19,318			22,577

Total assets	$	247,516		$	259,385


Liabilities and stockholder’s deficit
Current liabilities:
Line of credit	$	8,000		$	8,000
Accounts payable		15,665			18,103
Accrued expenses and other liabilities		24,579			25,492
Deferred tax liability		152			57
Deferred revenue		132			3,979

Total current liabilities		48,528			55,631
Asset retirement obligation		7,435			6,385
Long-term debt, net		399,280			399,037
Deferred tax liability		247			12
Other long-term liabilities		32,995			35,408

Total liabilities		488,485			496,473


Stockholder’s deficit		(240,969	)		(237,088	)

Total liabilities and stockholder’s deficit	$	247,516		$	259,385

###

Lantheus Medical Imaging, Inc. 8-K